474 related articles for article (PubMed ID: 30266938)
1. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis.
Zhao X; Zhu Y; Hu J; Jiang L; Li L; Jia S; Zen K
Sci Rep; 2018 Sep; 8(1):14517. PubMed ID: 30266938
[TBL] [Abstract][Full Text] [Related]
2. Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2.
Shankar Babu M; Mahanta S; Lakhter AJ; Hato T; Paul S; Naidu SR
PLoS One; 2018; 13(2):e0191419. PubMed ID: 29394289
[TBL] [Abstract][Full Text] [Related]
3. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.
Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G
Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397
[TBL] [Abstract][Full Text] [Related]
4. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line.
Yang W; Liu J; Hou L; Chen Q; Liu Y
Life Sci; 2021 Jan; 265():118796. PubMed ID: 33220292
[TBL] [Abstract][Full Text] [Related]
5. Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway.
Zhang J; Zhou J; Xiao S
Anticancer Drugs; 2020 Oct; 31(9):932-941. PubMed ID: 32282369
[TBL] [Abstract][Full Text] [Related]
6. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways.
Yang Q; Ji M; Guan H; Shi B; Hou P
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1909-17. PubMed ID: 24106286
[TBL] [Abstract][Full Text] [Related]
7. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.
Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X
Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121
[TBL] [Abstract][Full Text] [Related]
8. Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer.
Sha L; Lv Z; Liu Y; Zhang Y; Sui X; Wang T; Zhang H
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34109434
[TBL] [Abstract][Full Text] [Related]
9. Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation.
Zhang Q; Liu Q; Zheng S; Liu T; Yang L; Han X; Lu X
J Cancer; 2021; 12(16):4830-4840. PubMed ID: 34234853
[No Abstract] [Full Text] [Related]
10. Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
Chao TK; Huang TS; Liao YP; Huang RL; Su PH; Shen HY; Lai HC; Wang YC
PLoS One; 2017; 12(7):e0182166. PubMed ID: 28753677
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis.
Ding H; Jiang L; Xu J; Bai F; Zhou Y; Yuan Q; Luo J; Zen K; Yang J
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F561-F575. PubMed ID: 28228400
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.
Wang X; Zhang F; Wu XR
Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811
[TBL] [Abstract][Full Text] [Related]
13. Beta-elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation.
Pan Y; Wang W; Huang S; Ni W; Wei Z; Cao Y; Yu S; Jia Q; Wu Y; Chai C; Zheng Q; Zhang L; Wang A; Sun Z; Huang S; Wang S; Chen W; Lu Y
J Cell Mol Med; 2019 Oct; 23(10):6846-6858. PubMed ID: 31343107
[TBL] [Abstract][Full Text] [Related]
14. Tumor M2-PK: A novel urine marker of bladder cancer.
Liu W; Woolbright BL; Pirani K; Didde R; Abbott E; Kaushik G; Martin P; Hamilton-Reeves J; Taylor JA; Holzbeierlein JM; Anant S; Lee EK
PLoS One; 2019; 14(6):e0218737. PubMed ID: 31246990
[TBL] [Abstract][Full Text] [Related]
15. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice.
Shi HS; Li D; Zhang J; Wang YS; Yang L; Zhang HL; Wang XH; Mu B; Wang W; Ma Y; Guo FC; Wei YQ
Cancer Sci; 2010 Jun; 101(6):1447-53. PubMed ID: 20507318
[TBL] [Abstract][Full Text] [Related]
16. Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells.
Chang IC; Huang YJ; Chiang TI; Yeh CW; Hsu LS
Biol Pharm Bull; 2010; 33(5):816-24. PubMed ID: 20460760
[TBL] [Abstract][Full Text] [Related]
17. Interdependence of GLO I and PKM2 in the Metabolic shift to escape apoptosis in GLO I-dependent cancer cells.
Shimada N; Takasawa R; Tanuma SI
Arch Biochem Biophys; 2018 Jan; 638():1-7. PubMed ID: 29225125
[TBL] [Abstract][Full Text] [Related]
18. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Tang JC; Ren YG; Zhao J; Long F; Chen JY; Jiang Z
Life Sci; 2018 Jul; 204():71-77. PubMed ID: 29738778
[TBL] [Abstract][Full Text] [Related]
19. [Antitumor effect research progress of shikonin and its derivatives].
Zhu MY; Wang RB; Zhou W; Li SS
Yao Xue Xue Bao; 2012 May; 47(5):588-93. PubMed ID: 22812000
[TBL] [Abstract][Full Text] [Related]
20. Shikonin reverses cancer-associated fibroblast-induced gemcitabine resistance in pancreatic cancer cells by suppressing monocarboxylate transporter 4-mediated reverse Warburg effect.
Hu X; Peng X; Zhang Y; Fan S; Liu X; Song Y; Ren S; Chen L; Chen Y; Wang R; Peng J; Shen X; Chen Y
Phytomedicine; 2024 Jan; 123():155214. PubMed ID: 38134861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
